Edward J. Dulac III
2021
In 2021, Edward J. Dulac III earned a total compensation of $6.4M as Chief Financial Officer at Fate Therapeutics, a 12% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $168,000 |
|---|---|
| Option Awards | $500,000 |
| Salary | $420,000 |
| Stock Awards | $5,296,051 |
| Total | $6,384,051 |
Dulac received $5.3M in stock awards, accounting for 83% of the total pay in 2021.
Dulac also received $168K in non-equity incentive plan, $500K in option awards and $420K in salary.
Rankings
In 2021, Edward J. Dulac III's compensation ranked 1,993rd out of 12,406 executives tracked by ExecPay. In other words, Dulac earned more than 83.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,993 out of 12,406 | 84th |
Division Manufacturing | 757 out of 5,494 | 86th |
Major group Chemicals And Allied Products | 293 out of 2,369 | 88th |
Industry group Drugs | 252 out of 2,090 | 88th |
Industry Biological Products, Except Diagnostic Substances | 79 out of 452 | 83rd |
Source: SEC filing on April 25, 2022.
Dulac's colleagues
We found five more compensation records of executives who worked with Edward J. Dulac III at Fate Therapeutics in 2021.
2021
J Wolchko
Fate Therapeutics
Chief Executive Officer
2021
Mark Plavsic
Fate Therapeutics
Chief Technology Officer
2021
Bahram Valamehr
Fate Therapeutics
Chief Research and Development Officer
2021
Cindy Tahl
Fate Therapeutics
General Counsel
2021
Yu-Waye Chu
Fate Therapeutics